New Dangerous Medicine Warning: Reumofan Plus Pain Reliever

On June 1, 2012, the FDA issued a consumer warning about Reumofan Plus, a pain reliever manufactured in Mexico. The FDA questions the manufacturer's claims that it's a natural dietary supplement and that it poses no harmful side effects to those who take it. It's commonly taken to relieve arthritis pain and is available for sale over the Internet and in a limited number of retail stores.

The FDA's warning, found on the organization's website, says that Reumofan Plus "contains several active pharmaceutical ingredients not listed on the label that can be harmful." The FDA has analyzed the supplement and found it includes two specific ingredients that may pose serious health hazards:

  • Diclofenac sodium - used to treat pain and inflammatory disorders, such as arthritis, it is a non-steroidal anti-inflammatory drug (NSAID) and may increase the risk of heart attacks, strokes, and potentially fatal holes in the stomach and intestines
  • Methocarbomal - a muscle relaxant available by prescription that may cause dizziness, low blood pressure, and cause problems when driving or operating heavy machinery

The Mexican Ministry of Health has ordered a recall of Reumofan Plus following its discovery of corticosteroid dexamethasone in one batch. The harmful side effects of long-term use of corticosteroids may include diabetes, high blood pressure, ulcers, and muscle weakness.

The FDA advises those who are taking Reumofan Plus to stop taking it immediately and consult their physicians, and that no one should begin using it. The FDA has received numerous reports of health problems from those taking the pain reliever, including adverse kidney function and liver damage.

As with any defective pharmaceutical product, those who have experienced problems from Reumofan Plus may want to consult an attorney to pursue their legal rights to obtain compensation for any harm or damages they have suffered.


Recent Posts

Popular Categories



Jump to Page

By using this site, you agree to our updated Privacy Policy and our Terms of Use.